Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2020 Oct 19

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Panminerva Medica 2020 Oct 19

DOI: 10.23736/S0031-0808.20.04163-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Moving towards core antigen for the management of patients with overt and occult HBV infection

Angelo ARMANDI 1, Chiara ROSSO 1, Davide G. RIBALDONE, Gian P. CAVIGLIA 1

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Division of Gastroenterology, Città della Salute e della Scienza, Molinette Hospital, Turin, Italy


PDF


Chronic hepatitis B virus (HBV) infection encompasses a wide virologic and clinical spectrum with heterogeneous outcomes. The natural history of chronic HBV infection ranges from an inactive carrier state (hepatitis B e antigen-negative chronic infection) to progressive chronic hepatitis that may evolve in end-stage liver disease and hepatocellular carcinoma. The issue becomes even more complicated when we consider the unique biology of the virus; the HBV covalently-closed-circular DNA, that acts as virus transcription template, is the key factor responsible of the persistence of the infection even after hepatitis B surface antigen loss. In the last decade, novel serological and immunological biomarkers associated to the core protein of HBV have been approached in different clinical conditions. Remarkable results have been obtained both in the setting of overt and occult HBV infection. Here, we reviewed the meaning and the potential clinical applications of the measurement of core antigen and antibodies.


KEY WORDS: Antiviral therapy; Anti-HBc; Biomarkers; HBcrAg; HBV cccDNA

inizio pagina